Onkologie. 2024:18(2):121-124 | DOI: 10.36290/xon.2024.022
Ruxolitinib in treating polycythemia vera: what is it that we do not know yet?
- IV. interní hematologická klinika, FN Hradec Králové
Polycythemia vera (PV) is a frequent Ph-negative myeloproliferative disease where the primary therapeutic goals are to reduce and maintain haematocrit below 0.45 and to reduce the risk of developing thrombotic or haemorrhagic complications. Patients are classified into low-risk and high-risk categories according to age and a past thrombotic event. In low-risk patients, only venepuncture can be performed, but in the case of its infeasibility or a significant increase in leukocytes and thrombocytes or progression of splenomegaly, initiation of cytoreductive therapy is indicated. Cytoreductive therapy is always indicated for the treatment of high-risk PV patients and involves treatment with interferon (younger patients) or hydroxyurea (elderly patients). Treatment with acetylsalicylic acid is always commenced in all patients. Ruxolitinib is a Janus kinase 1/2 inhibitor and is a treatment option when resistance or intolerance to first-line drugs develop (1-3).
Keywords: JAK1/2 inhibitors, treatment, polycythemia vera, ruxolitinib.
Accepted: April 19, 2024; Published: May 3, 2024 Show citation
References
- Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465-1487. doi: 10.1002/ajh.27002.
Go to original source... 
Go to PubMed... - Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev. 2020;42:100714. doi: 10.1016/j.blre.2020.100714. Go to original source... Go to PubMed...
- Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477.
- JAKAVI SPC. Available from: https://ec.europa.eu/health/documents/community-register/2012/20120823123254/anx_123254_cs.pdf.
- Harrison CN, Kiladjian JJ, Palandri F, et al. Ruxolitinib Treatment in Polycythemia Vera Results in Reduction in JAK2 Allele Burden in Addition to Improvement in Hematocrit Control and Symptom Burden. ASH 2023, abstract 4553. Go to original source...
- Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Go to original source... Go to PubMed...
- Koschmieder S, Isfort S, Lino L, et al. Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN), ASH 2023, abstract 619. Go to original source...
- Duminuco A, Harrington P, Harrison C, et al. Polycythemia Vera: Barriers to and Strategies for Optimal Management. Blood Lymphat Cancer. 2023;13:77-90. doi: 10.2147/BLCTT.S409443. Go to original source... Go to PubMed...